Amyotrophic Lateral Sclerosis: Current Diagnosis, Treatment and Management

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378041%3A_____%2F16%3A00475924" target="_blank" >RIV/68378041:_____/16:00475924 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Amyotrophic Lateral Sclerosis: Current Diagnosis, Treatment and Management

Popis výsledku v původním jazyce

The clinical featurec of amyotrophic lateral sclerosis (ALS) consists of progressive neurological deteriorations that reflect the impairment and subsequent loss of muscle functions, resulting from the death of motor neurons in the corticospinal tract, brain stem or the ventral horns of the spinal cord. Up to now several electrophysiological and neuroimaging indicators of manifested ALS have been developed, but only candidate biomarkers have been suggested to have a potential role in the diagnosis and prognosis of ALS, with further testing needed. Currently, there is no clinically relevant treatment available for ALS. The therapeutic strategies comprise a neuroprotective treatment focused on antiglutamatergic, antioxidant, antiapoptotic, anti-inflammatory and neurotrophic molecules, as on well as gene therapy and stem cell application.

Název v anglickém jazyce

Amyotrophic Lateral Sclerosis: Current Diagnosis, Treatment and Management

Popis výsledku anglicky

The clinical featurec of amyotrophic lateral sclerosis (ALS) consists of progressive neurological deteriorations that reflect the impairment and subsequent loss of muscle functions, resulting from the death of motor neurons in the corticospinal tract, brain stem or the ventral horns of the spinal cord. Up to now several electrophysiological and neuroimaging indicators of manifested ALS have been developed, but only candidate biomarkers have been suggested to have a potential role in the diagnosis and prognosis of ALS, with further testing needed. Currently, there is no clinically relevant treatment available for ALS. The therapeutic strategies comprise a neuroprotective treatment focused on antiglutamatergic, antioxidant, antiapoptotic, anti-inflammatory and neurotrophic molecules, as on well as gene therapy and stem cell application.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

30210 - Clinical neurology

Projekt

<a href="/cs/project/LO1309" target="_blank" >LO1309: Buněčná terapie a tkáňové náhrady</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Novel Biomaterials in Regenerative Medicine

ISBN

978-80-88113-69-0

Počet stran výsledku

14

Strana od-do

93-106

Počet stran knihy

276

Název nakladatele

Epika

Místo vydání

2016

Kód UT WoS kapitoly

—